



**Work With a Leader in Autologous Collections  
That Can Support the Development, Launch,  
and Growth of Your Therapy**



**American  
Red Cross**


Cell and Gene  
Therapy Solutions

## Our Nationwide Footprint Helps Smooth Out Logistics and Supports Patient Access

With over 30 years of apheresis collections experience, the American Red Cross is uniquely positioned to serve the market as a single-source provider for autologous collections. We provide collection services in support of all FDA Approved T-Cell Therapies as well as investigational drugs under evaluation in clinical trials. We have completed more than 50,000 collection procedures for autologous therapies at 72 Red Cross sites across the United States and at multiple hospital locations. As an essential business, our sites continue to operate throughout the pandemic, putting necessary procedures in place to keep patients safe and secure to ensure collections continue as scheduled.

With a centrally managed nationwide apheresis network of 72 fixed sites, the Red Cross is the largest single provider of autologous Mononuclear Cell Collections (MNC) in the United States. Our national footprint of collection centers allows for risk mitigation if a given site is unavailable. This ability reduces supply-chain disruptions often caused by patient apheresis appointment delays and enables us to reduce the time between donor collection and receipt of delivery—minimizing the shipping distances for organizations using multiple manufacturing sites and processing centers, keeping development costs down, and smoothing out logistics for manufacturing.

Red Cross has the expertise to provide high-quality source material for your therapy from discovery through commercialization. As you develop, launch, and grow your therapy, we can provide economies of scale, significant expansion capability, and consolidated account management to support you every step along the way.



## Success Story:

Our national network of blood collection centers provides convenient access to services for PROVENGE® patients and helps Dendreon facilitate the successful commercial delivery of PROVENGE nationwide.

**“Since 2010 the American Red Cross has played an essential role in the delivery of PROVENGE® (sipuleucel-T)—an autologous cellular immunotherapy for the treatment of men with advanced prostate cancer. Their national network of blood collection centers facilitate the successful commercial delivery of PROVENGE and ensure convenient access to services for PROVENGE patients nationwide. We are grateful to the American Red Cross for their support and strong partnership. Equally innovative and reliable, we value their expertise, attention to detail and shared commitment to our patients.”**

**—Serena Stewart | Vice President, Patient Operations Dendreon Pharmaceuticals**



## Streamlined Audits and Site On-Boarding

All Red Cross collection sites operate under one Quality Management System (QMS) and one set of national procedures, resulting in a streamlined audit process for our clients. Our national approach supports customers performing one single systemwide audit, with local site audits focused primarily on the review of individual-site items, such as local staff training and equipment records.

Our national policies and processes related to staff training ensure that collections align with client-specific leukapheresis manuals and those collection procedures remain consistent across sites. The Red Cross has experience in implementing the full suite of potential customizations contained in our client's leukapheresis manuals which go beyond the collection procedure parameters, including client-specific product sampling and testing, patient testing, and compliance with your standard packaging and shipping requirements.

## A Dedicated Client Team With Extensive Experienced in Apheresis Collections

A dedicated Client Relationship Management team at the American Red Cross provides a single point of contact for our clients and ensures standardization in services across our nationwide sites. Utilization of staff across geographies ensures appropriate nationwide coverage, regardless of uneven demand.

Our ability to perform autologous MNC collections across the country allows our clients to offer subjects enrolled in their studies geographical convenience, which may lead to increased enrollment and subject retention. Our skilled nursing staff is experienced in apheresis collections performed via peripheral or Central Venous Catheter (CVC) access. Our standard leukapheresis educational materials help inform physicians and patients on what to expect during a collection procedure and how best to prepare for an optimal experience. Our expertise in providing hospital-based therapeutic apheresis and stem cell collections services allows us to provide in-hospital collections when needed.



## Testing, Cell Processing, Cryopreservation and Storage Services

Our full-service cellular therapy labs across the country perform processing, freezing, and storage of mononuclear cell products according to either your protocol or Red Cross protocols. If required, the products can be frozen before shipment or be stored at a Red Cross facility. Product testing can be provided, including sterility, viability, endotoxin, and immunophenotyping, as well as other custom requests. We offer same-day processing and cryo-preservation post-collection in select geographies. Leukapheresis material can be packaged according to client specifications and shipped fresh or frozen.

## We Provide a Full-Service Offering Which Supports Prescribing Physicians, Principal Investigators, and Patients

- Physician and patient education on leukapheresis procedures
- Venous assessment
- Central venous catheter care, including dressing changes
- Provision and utilization of heparin to lock catheter
- For multiple procedures, CBC sample draw, and testing
- Per procedure review of CBC results and relevant medical history
- Post-procedure feedback to prescribing physician or principal investigator
- Access to industry-recognized medical proficiency

## Red Cross Supports Your Therapy From Discovery Through Commercialization

Clinical Phase 1	Clinical Phase 2	Clinical Phase 3	Commercial
<ul style="list-style-type: none"><li>▪ Support addition of new PI's and local apheresis access for patients... 72 sites and growing</li><li>▪ Informational materials for PI's and research subjects</li><li>▪ Collections can be performed in hospitals, hosting site or PI facility</li><li>▪ Support onboarding of apheresis sites with train the trainer capability</li><li>▪ Nationwide Red Cross RN coverage</li></ul>			<p>Coordinated launch of additional sites as needed to support commercialization of your therapy...400+ Red Cross fixed sites</p> <p>Informational materials for physicians and patients</p>

## Flexible Contracting Arrangements

The American Red Cross offers direct contracting with trial sponsors or hosting institutions to enable rapid onboarding of new principal investigators while providing a direct billing structure that improves cost management.

## We Are Committed to Your Success

The American Red Cross is committed to supporting the development, launch, and provision of cell and gene therapies. We are the largest single provider of autologous MNC collections in the United States, performing thousands of procedures each year in support of these life-saving therapies. Contact us at 833-760-0625 to discuss your autologous MNC collection needs and learn how we can partner with you to ensure quality and consistency with your starting material.

Visit [RedCrossBlood.org/MNCCollections](https://RedCrossBlood.org/MNCCollections) or call **833-760-0625** to learn more.